WOW.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Cencora - Wikipedia

    en.wikipedia.org/wiki/Cencora

    Financials as of September 30, 2023. [update] [1] Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale company and a contract research organization that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. [2]

  3. PharMerica - Wikipedia

    en.wikipedia.org/wiki/PharMerica

    PharMerica. PharMerica is a Fortune 1000 company formed in January 2007 from the merger of Kindred Healthcare 's pharmacy business with a subsidiary of AmerisourceBergen. [1] The company is headquartered in Louisville, Kentucky, and operates a major customer support center in Tampa, Florida. [2]

  4. AOL Mail

    mail.aol.com

    Absolutely! It's quick and easy to sign up for a free AOL account. With your AOL account you get features like AOL Mail, news, and weather for free!

  5. AmerisourceBergen (ABC) Hits Fresh High: Is There Still Room ...

    www.aol.com/news/amerisourcebergen-abc-hits...

    AmerisourceBergen (ABC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  6. Is AmerisourceBergen (ABC) a Good Stock for Value Investors?

    www.aol.com/news/amerisourcebergen-abc-good...

    Let's see if AmerisourceBergen Corporation (ABC) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

  7. Need help? Call us! 800-290-4726 Login / Join. Mail

  8. AmerisourceBergen Corporation - Wikipedia

    en.wikipedia.org/?title=AmerisourceBergen...

    This page was last edited on 31 August 2023, at 09:27 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may ...

  9. AmerisourceBergen (ABC) Upgraded to Buy: Here's Why - AOL

    www.aol.com/news/amerisourcebergen-abc-upgraded...

    AmerisourceBergen (ABC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).